Source: Guanlan Pharmaceutical
Recently, Zhimeng Pharmaceutical announced that the US FDA has approved the clinical trial application of its small molecule oral TLR8 agonist CB06-036
.
CB06-036 is a drug candidate for the treatment of chronic hepatitis B, independently developed by Zhimeng Pharmaceutical
.
As a TLR8 agonist, CB06-036 has shown good selectivity, activity and safety in preclinical studies.
It can induce cytokines in human peripheral blood mononuclear cells.
These cytokines can pass through a variety of immune mediators.
, Activate the anti-virus function
.
At the same time, it has also been found to have good liver targeting characteristics
.
Based on this license, Zhimeng Medicine is about to start a phase 1 clinical trial in the United States, which will use healthy volunteers as subjects to evaluate the safety and tolerability of CB06-036 after oral ascending doses, and to determine the effectiveness of the drug in the body.
Research on kinetics and pharmacodynamics
.
